Every material Form 8-K IRADIMED CORP has filed with the SEC since May 01, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
IRADIMED reported third-quarter 2026 revenue of $24.2 million, up 14% from a year earlier, and GAAP diluted EPS of $0.51 versus $0.43. The company narrowed its full-year 2026 guidance, lowering the top end of its revenue and GAAP EPS ranges, which matters to shareholders because the outlook for the rest of the year is now less generous at the high end.
Q3 2026 revenue of $24.2 million, up from $21.2 million; net income of $6.5 million versus $5.6 million
Full-year 2026 revenue guidance changed to $91.6 million to $93.1 million from $91.0 million to $96.0 million
Full-year 2026 GAAP diluted EPS guidance changed to $1.90 to $1.94 from $1.90 to $2.05
Quarterly cash dividend of $0.20 per share, payable November 27, 2026 to holders of record on November 13, 2026
IRADIMED reported second-quarter 2026 revenue of $20.5 million, up 0.5% from a year earlier, while net income fell 10% to $5.2 million and diluted EPS fell to $0.41 from $0.45. The company reaffirmed its full-year 2026 revenue and EPS guidance and declared a $0.20 per share quarterly dividend. Management said the first production ramp of the new 3870 IV pump met its plan, and the quarterly gross profit margin fell to 74% from 78%.
Q2 2026 revenue was $20.5 million, up $0.1 million from $20.4 million in Q2 2025.
Q2 2026 GAAP diluted EPS was $0.41 versus $0.45 a year earlier; non-GAAP diluted EPS was $0.46 versus $0.49.
Full-year 2026 guidance reaffirmed: revenue of $91.0 million to $96.0 million and GAAP diluted EPS of $1.90 to $2.05.
Q3 2026 guidance: revenue of $23.0 million to $24.5 million and GAAP diluted EPS of $0.49 to $0.54.
Iradimed reported first-quarter 2026 revenue of $22.0 million, up 13%, and record GAAP diluted EPS of $0.45, up 22%. The company reaffirmed its full-year 2026 guidance and declared a $0.20 per share quarterly dividend, but its second-quarter 2026 revenue guidance of $20.0 million to $21.0 million sits below the first-quarter result.
Q1 2026 revenue was $22.0 million, up from $19.5 million; net income was $5.8 million, or $0.45 per diluted share, versus $0.37 a year earlier
Full-year 2026 guidance reaffirmed: revenue of $91.0 million to $96.0 million and GAAP diluted EPS of $1.90 to $2.05
Q2 2026 guidance: revenue of $20.0 million to $21.0 million and GAAP diluted EPS of $0.40 to $0.44
Quarterly dividend of $0.20 per share, record date May 15, 2026, payable May 29, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every IRADIMED CORP filing is on SEC EDGAR ↗. 8-K briefs of other companies →